FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

A longitudinal study of cerebral gray matter volume in patients receiving Tysabri (natalizumab) for multiple sclerosis: STUDY







































Abstract

Objective:
To assess the change in cerebral gray matter volume (GMV) during one year of Tysabri therapy in patients with multiple sclerosis (MS). BACKGROUND: Brain atrophy in patients with MS selectively affects the gray matter (GM). Several studies have shown the high clinical relevance of GM atrophy in predicting physical disability and cognitive impairment. The effect of disease-modifying therapies on such atrophy has not been extensively studied.

Design/Methods:
We retrospectively identified 20 consecutive patients who had 1.5T brain MRI ~1 year apart during treatment with Tysabri The patients had relapsing-remitting (n=18) or progressive (n=2) forms of MS. At the time of the first scan, the patients had been on Tysabri for (mean±SD) 16.6±10.9 months. Baseline characteristics were age 38.5±7.4 and disease duration 9.7±4.3 years; six (30[percnt]) were men. GMV was determined by a semi-automated technique using output from a template driven segmentation.

Results:
At baseline, GMV was 664.0±56.4 ml, Expanded Disability Status Scale (EDSS) score was 2.3±2.0 and timed 25 foot walk (T25FW) was 6.1±3.4 seconds. At follow-up, GMV was 664.03±60.08 mL; EDSS was 2.6±2.1 and T25FW was 5.9±2.9 seconds. One sample t-tests showed no significant annualized change in GMV [estimated mean difference -0.17, 95[percnt] confidence interval (CI) -10.49, 10.15, p=0.97)], EDSS (estimated mean difference 0.38, 95[percnt] CI -0.15, 0.91, p=0.15), or T25FW (estimated mean difference -0.22, 95[percnt] CI -1.14, 0.70, p=0.63). No patients had clinical relapses during the observation period.

Conclusions:
This pilot study shows the lack of cerebral GM atrophy during one year of Tysabri therapy in patients with MS. The lack of GM atrophy paralleled the lack of clinical worsening in terms of relapses or change in physical disability measures. Further controlled prospective comparison group studies with larger sample sizes and longer study durations are necessary to confirm and extend these results. Study Supported by: Biogen, Inc.

Story Source: The above story is based on materials provided by NEUROLOGY
Note: Materials may be edited for content and length
Click here to read original article

Labels: ,



Go to Newer News Go to Older News